ArticleFrontiers in behavioral neuroscience2025
Comparison of ziprasidone and olanzapine on cognitive function in patients with schizophrenia at different stages: a prospective study in Huai'an, China.
Article in Frontiers in behavioral neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the effects of ziprasidone and olanzapine on cognitive function in patients with first-episode schizophrenia and chronic schizophrenia at different stages. Methods: Cognitive function tests were performed on chronic schizophrenic patients who took olanzapine for a long time, first-episode drug-free schizophrenic patients, and healthy controls. Results: There were significant differences in the digit span test, Stroop color and word test, auditory verbal learning test N2, N3, N4, trail-making test, verbal fluency test, and clock drawing test between first-episode drug-free schizophrenic patients and healthy controls ( Conclusion: Patients with schizophrenia have cognitive dysfunction in the early stage of onset. The combination of ziprasidone and olanzapine can effectively improve cognitive dysfunction and promote the recovery of social functions of patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.